Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3428]

Targeting CDK pathways in cancer treatment

Dr Geoffrey Shapiro - Dana Farber Cancer Institute, Boston, USA

Targeting CDK pathways in cancer treatment ( Dr Geoffrey Shapiro - Dana Farber Cancer Institute, Boston, USA )

Refining the role of PARP inhibitors in targeted anticancer therapy

Prof Yves Pommier - National Cancer Institute, Bethesda, USA

Refining the role of PARP inhibitors in targeted anticancer therapy ( Prof Yves Pommier - National Cancer Institute, Bethesda, USA )

Developments in immunotherapy

Prof Lillian Siu - University Health Network, Toronto, Canada

Developments in immunotherapy ( Prof Lillian Siu - University Health Network, Toronto, Canada )

Combining immunotherapies: inhibiting the CTLA-4 and PD-1 pathways

Prof Mario Sznol - Yale Cancer Center, New Haven, USA

Combining immunotherapies: inhibiting the CTLA-4 and PD-1 pathways ( Prof Mario Sznol - Yale Cancer Center, New Haven, USA )

Discovering selective anticancer drugs: succeeding slowly is better than...

Professor Hilary Calvert - UCL Cancer Institute, London, UK

Discovering selective anticancer drugs: succeeding slowly is better than failing fast ( Professor Hilary Calvert - UCL Cancer Institute, London, UK )

Mutant-specific kinase inhibitors and TAT highlights

Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France

Mutant-specific kinase inhibitors and TAT highlights ( Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France )

Drugging the cancer genome to overcome drug resistance

Prof Paul Workman - Institute of Cancer Research, UK

Drugging the cancer genome to overcome drug resistance ( Prof Paul Workman - Institute of Cancer Research, UK )

ecancermedicalscience editor's choice for February 2015

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ecancermedicalscience editor's choice for February 2015 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in...

Dr Mark Beresford - Royal United Hospitals Bath, Bath, UK

Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in localised renal carcinoma ( Dr Mark Beresford - Royal United Hospitals Bath, Bath, UK )

Expert commentary on emerging research in genitourinary cancer

Dr Chris Parker - The Royal Marsden Hospital, London, UK

Expert commentary on emerging research in genitourinary cancer ( Dr Chris Parker - The Royal Marsden Hospital, London, UK )

Combination of dalantercept plus axitinib versus placebo plus axitinib in...

Dr Martin Voss - Memorial Sloan Kettering Cancer Centre, New York City, USA

Combination of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma ( Dr Martin Voss - Memorial Sloan Kettering Cancer Centre, New York City, USA )

VEGF targeted therapy and chemo an active combination in rapidly progressive...

Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA

VEGF targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma ( Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer